Previous close | 7.95 |
Open | 7.91 |
Bid | 9.59 x 1800 |
Ask | 10.01 x 800 |
Day's range | 7.41 - 7.91 |
52-week range | 5.95 - 19.23 |
Volume | |
Avg. volume | 1,044,338 |
Market cap | 983.842M |
Beta (5Y monthly) | 1.66 |
PE ratio (TTM) | N/A |
EPS (TTM) | -2.79 |
Earnings date | 02 May 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 23.05 |
In this article, we will be taking a look at 11 oversold biotech stocks to buy right now. To skip our detailed analysis of the biotech sector, you can go directly to see the 5 Oversold Biotech Stocks To Buy Right Now. Dealmaking in Biotech Healthcare has been performing well so far in 2024, and […]
The mean of analysts' price targets for Relay Therapeutics, Inc. (RLAY) points to a 146.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
CAMBRIDGE, Mass., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, today announced that management will participate in three upcoming fireside chats: TD Cowen’s 44th Annual Health Care Conference on Monday, March 4, 2024 at 10:30 a.m. ETLeerink Partners’ 2024 Global Biopharma Conference on Monday, March 11, 2024 at 10